![](https://endpts.com/wp-content/uploads/2017/07/protocols-two.jpg)
Merck scores priority review Keytruda in squamous NSCLC; Synthetic Genomics spinout SGI-DNA gets new CEO
→ The FDA has accepted — and given priority review — to Merck’s supplemental biologics license application for its cancer immunotherapy Keytruda. The pharma giant is hoping …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.